1. Scrip
  2. >>R&D

BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic

 
• By Vibha Ravi

Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics

BioAsia 2023 Panel On One Health Approach
BioAsia Panel Participants (Seated L to R) - Sai D Prasad (Bharat Biotech), Mahender Nayak (Takeda), V K Paul (NITI Aayog), Cynthia McCaffrey (UNICEF), Samit Hirawat (Bristol Myers), Richard Hatchett (CEPI). Moderator Gagandeep Kang (CMC) On Screen • Source: Scrip Norstella

“COVID-19 is gone, long live COVID” – this is not a proverb, thankfully so. But it could be, given that the global pharma industry is still drawing lessons from the pandemic caused by SARS-CoV-2 to prepare for the next one, which many in the scientific community say is inevitable.

A panel of officials from companies, regulators and multilateral organizations came together with scientists at a recent conference to consider...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from R&D

ESMO 25: Tolerability Raised As Exelixis STELLAR-303 Study Still Needs To Mature

 
• By Alexandra Shimmings

Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.

Sanofi’s Inhibrx-Acquired Rare Disease Therapy Clears Phase II Hurdle

 
• By Manas Mishra

Efdoralprin alfa, which was acquired through Inhibrx, has met the endpoints of a Phase II trial for alpha-1 antitrypsin deficiency.

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

More from Scrip

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.